Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q1 2024 · 10-Q
Revenue$25.36M$25.36M−29.9% vs Q1 2023 Net Income-$32.93M-$32.93MN/M vs Q1 2023 EPS Diluted-$0.33-$0.33N/M vs Q1 2023 Operating Income-$49,182,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
Free Cash Flowderived-$59,317,000N/M Margins · derivedOperating margin-193.9%+16.5 pt vs Q1 2023
Net margin-129.8%+82.3 pt vs Q1 2023
ended Mar 31, 2024 · filed May 6, 2024 · 36 d after period end